1. Detecting autoreactive B cells in the peripheral blood of people with type 1 diabetes using ELISpot
- Author
-
Stephanie J. Hanna, Claire N. Hocter, M. D. Lewis, Wendy Powell, Gareth Dunseath, A. Howell, Colin M. Dayan, Florence Susan Wong, Stephen D. Luzio, and Emma J. S. Robinson
- Subjects
0301 basic medicine ,Enzyme-Linked Immunospot Assay ,Immunology ,Glutamate decarboxylase ,Autoantigens ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,Immunology and Allergy ,Medicine ,Humans ,Receptor-Like Protein Tyrosine Phosphatases, Class 8 ,B cell ,Autoantibodies ,Type 1 diabetes ,geography ,B-Lymphocytes ,geography.geographical_feature_category ,biology ,business.industry ,Glutamate Decarboxylase ,ELISPOT ,Autoantibody ,Reproducibility of Results ,medicine.disease ,Islet ,030104 developmental biology ,medicine.anatomical_structure ,Diabetes Mellitus, Type 1 ,biology.protein ,Antibody ,business ,030215 immunology - Abstract
Type 1 diabetes mellitus (T1D) is an autoimmune disorder where T lymphocytes damage the islet beta cells but B lymphocytes also play an important role. Although changes in peripheral B cell phenotype have been observed, little is known about the B cells that secrete the autoantibodies. We developed a sensitive B cell enzyme-linked immunospot assay (ELISpot assay) to detect individual B cell antibody responses to glutamic acid decarboxylase (GAD) and islet antigen-2 (IA-2). We found that even healthy donors have B cells that secrete antibodies in response to GAD and IA-2 in the ELISpot. There was increased B cell reactivity to autoantigens in the peripheral blood of individuals with newly-diagnosed, but not long-standing, type 1 diabetes. However, no correlation with serum autoantibody levels was found, indicating that additional factors such as antigen affinity or exposure to antigens in vivo are required for antibody secretion, and that even healthy donors have potentially autoreactive B cells.
- Published
- 2019